Docket No.: 1422-0720PUS1

AMENDED SET OF CLAIMS

Please amend the claims as follows:

1-11. (Cancelled).

12. (Currently Amended) A method for preventing, ameliorating or treating a bowel disease,

comprising

administering the a composition comprising galactomannan and/or arabinogalactan of

elaim 1 to a patient suffering from said bowel disease.

13. (Previously Presented) The method according to claim 12, wherein the bowel disease is

an inflammatory bowel disease.

14. (Previously Presented) The method according to claim 12, wherein said galactomannan

and/or arabinogalactan is administered with a protein.

15. (Previously Presented) The method according to claim 14, wherein the protein is one or

more proteins selected from the group consisting of a soy protein, a milk protein, a yolk protein,

an albumen protein, a wheat protein and a degraded product thereof.

16. (Currently Amended) A method for preventing, ameliorating or treating The method

according to claim-12, wherein the bowel disease is irritable bowel syndrome, comprising

Application No.: 10/582,323

Amendment dated January 14, 2009

Reply to Office Action of August 14, 2008

administering a composition comprising galactomannan to a patient suffering from said

irritable bowel syndrome.

17. (Currently Amended) The method according to claim 14 12, wherein said composition is

administered as a liquid food.

18. (New) The method according to claim 12, wherein the composition comprises degraded

galactomannan as the galactomannan.

19. (New) The method according to claim 14, wherein said galactomannan is degraded

galactomannan.

20. (New) The method according to claim 16, wherein the composition comprises degraded

galactomannan as the galactomannan.

21. (New) The method according to claim 13, wherein said inflammatory bowel disease is

selected from the group consisting of ulcerative colitis, Crohn's disease and intestinal Behçet

disease.

22. (New) The method according to claim 14, wherein said inflammatory bowel disease is

selected from the group consisting of ulcerative colitis, Crohn's disease and intestinal Behçet

disease.

Docket No.: 1422-0720PUS1

Application No.: 10/582,323

Amendment dated January 14, 2009

Reply to Office Action of August 14, 2008

23. (New) The method according to claim 12, wherein said method is for ameliorating or

treating said bowel disease.

24. (New) The method according to claim 14, wherein said method is for ameliorating or

treating said bowel disease.

25. (New) The method according to claim 16, wherein said method is for ameliorating or

treating said irritable bowel syndrome.

26. (New) The method according to claim 12, wherein said composition comprises

galactomannan and does not comprise arabinogalactan.

27. (New) The method according to claim 12, wherein said composition comprises

arabinogalactan and does not comprise galactomannan.

28. (New) The method according to claim 12, wherein said composition comprises

4 .

galactomannan and arabinogalactan.

Docket No.: 1422-0720PUS1